Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of anle138b in Mild to Moderate Parkinson's Disease
NCT04685265Phase 1Completed
- Sponsor
- MODAG
- Start
- Dec 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing anle138b with Placebo (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of treatment-emergent changes in vital signs and 3 more. Started Dec 2020; status: completed.
02
Drugs
emrusolmin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04685265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04685265.